Subscribe

medcelerator

Accelerating medical breakthroughs to patients

Understand new treatments and trials: who they may help, what the evidence shows, and how access differs by country.

Find by condition

Show treatments for

FDA ApprovedUnited States, European Union

Pill for Teens and Adults with Severe Alopecia Areata

Olumiant (baricitinib) — once-daily pill for teens and adults with severe alopecia areata

This is for families and adults living with severe alopecia areata who are 12 years or older. It explains the US prescribing-information expansion in September 2026 that added adolescents to Olumiant (baricitinib), the EU SmPC adolescent wording, the once-daily oral path through dermatology, and what BRAVE-AA-PEDS showed. It is not an under-12 approval, not a cream, and not a reason to skip infection and lab screening. Authorized is not funded.

FDA ApprovedUnited StatesUnited KingdomEuropean Union

First FDA-Approved Eye Form of Bevacizumab for Wet AMD

Lytenava (bevacizumab-vikg) — ophthalmic VEGF inhibitor injection for wet age-related macular degeneration

This is for adults with wet age-related macular degeneration who may be candidates for labelled US Lytenava monthly eye injections — the first FDA-approved ophthalmic bevacizumab made for the eye.

Health Canada/FDA ApprovedUnited StatesCanadaJapanEuropean Union

New Pill for Hormone-Positive Advanced Breast Cancer

Etcamah (camizestrant) — oral ER antagonist with CDK4/6 for ESR1m HR+/HER2− advanced breast cancer

This is for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer who are already on an aromatase inhibitor plus a CDK4/6 inhibitor and whose blood ctDNA test shows an…

Health Canada/FDA ApprovedUnited StatesCanadaJapanChinaAustraliaSwitzerlandEuropean Union

Once-Weekly Insulin Shot for Adults with Type 2 Diabetes

Awiqli (insulin icodec / insulin icodec-abae) — once-weekly basal insulin

The first labelled once-weekly basal insulin. The United States (FDA, 26 Mar 2026) labels it only for adults with type 2 diabetes as an adjunct to diet and exercise for glycemic control.

Breakthrough Brief

New treatments and trials, weekly. Every email has an unsubscribe link.

By subscribing, you request Breakthrough Brief emails. Privacy

Special series

Breaking Out: The Weight Class — Shots, Pills, and Organ Labels in 2026

Shots, pills, and organ labels in the 2026 weight class — Wegovy injection, Zepbound, the oral maze, and the process line that authorized is not funded. International by default. Zoom by country. Authorized is not funded.

Enter the seriesAll series

Treatment types

The next wave of treatment

All treatment types →

Gene Therapy

Cell Therapy

GLP-1

Glucagon-like peptide-1 (and dual GIP/GLP-1) medicines for diabetes, weight, and labelled organ-protection uses. Authorized is not funded.

More breakthroughs

NewestPatient Stories
Health Canada/FDA ApprovedUnited StatesCanadaUnited KingdomJapanAustraliaSwitzerlandEuropean Union

New Pill for Chronic Hives Not Controlled by Antihistamines

Rhapsido (remibrutinib) for adult chronic spontaneous urticaria still active on H1 antihistamines

The FDA, Health Canada, the European Commission, and the UK MHRA have labelled an oral BTK inhibitor — 25 mg twice daily — for adults with chronic spontaneous urticaria that is still active on H1…

Health Canada/FDA ApprovedUnited StatesCanadaEuropean Union

First FDA-Approved Treatment for Chronic Hepatitis D

Hepcludex (bulevirtide) for chronic hepatitis D (HDV)

The first labelled drug for chronic hepatitis D. The United States (FDA accelerated, 22 May 2026) labels 8.5 mg subcutaneously once daily for adults without cirrhosis or with compensated cirrhosis.

Health Canada/FDA ApprovedUnited StatesCanadaUnited KingdomJapanAustraliaEuropean Union

Twice-Yearly Shot for a Severe Type of Asthma

Exdensur (depemokimab) for severe eosinophilic asthma — and, outside the United States, for nasal polyps

The FDA, Health Canada, the UK MHRA, Japan’s MHLW, the EU Commission, and (on the Australian PI) the TGA have labelled a twice-yearly anti-IL-5 injection.

FDA ApprovedUnited StatesCanadaUnited KingdomEuropean Union

New Pill for Scarred-Lung Disease in Adults

Jascayd (nerandomilast) for IPF and PPF

The FDA, Europe, and the UK have labelled nerandomilast for adults with idiopathic pulmonary fibrosis and for adults with progressive pulmonary fibrosis.

FDA ApprovedUnited StatesCanadaUnited KingdomChinaEuropean Union

New Pill When the Heart Muscle Is Too Thick

Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy

The FDA, Europe, the UK, and China have labelled aficamten for symptomatic obstructive HCM in adults. England's NHS has a 30-day funding clock from NICE.

See all latest